Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Lobular | 3 | 2017 | 85 | 0.580 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2017 | 166 | 0.550 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2014 | 125 | 0.440 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2012 | 188 | 0.330 |
Why?
|
| Breast Neoplasms | 4 | 2017 | 3142 | 0.260 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2011 | 1173 | 0.190 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2012 | 37 | 0.180 |
Why?
|
| Carcinoma | 2 | 2012 | 449 | 0.150 |
Why?
|
| Lung Neoplasms | 2 | 2011 | 2464 | 0.140 |
Why?
|
| Pneumonectomy | 2 | 2011 | 222 | 0.130 |
Why?
|
| Radiotherapy, Conformal | 1 | 2017 | 89 | 0.130 |
Why?
|
| Brachytherapy | 2 | 2014 | 127 | 0.120 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 2420 | 0.120 |
Why?
|
| Neoplasm Grading | 2 | 2014 | 403 | 0.110 |
Why?
|
| ErbB Receptors | 1 | 2016 | 516 | 0.100 |
Why?
|
| Prognosis | 4 | 2017 | 4024 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2014 | 7205 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 3901 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 1461 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2014 | 1006 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 1105 | 0.080 |
Why?
|
| Radiotherapy | 2 | 2012 | 328 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2012 | 2082 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 1088 | 0.080 |
Why?
|
| Interferons | 1 | 2008 | 130 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2017 | 10190 | 0.070 |
Why?
|
| Aged | 5 | 2017 | 20877 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2012 | 1765 | 0.070 |
Why?
|
| Platinum Compounds | 1 | 2007 | 28 | 0.070 |
Why?
|
| DNA Damage | 1 | 2008 | 392 | 0.060 |
Why?
|
| Middle Aged | 5 | 2017 | 28255 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2007 | 444 | 0.050 |
Why?
|
| Endoscopy, Digestive System | 2 | 2012 | 72 | 0.050 |
Why?
|
| Biomarkers | 1 | 2008 | 1933 | 0.050 |
Why?
|
| Female | 5 | 2017 | 49947 | 0.050 |
Why?
|
| Humans | 9 | 2017 | 95984 | 0.040 |
Why?
|
| Adult | 3 | 2014 | 28637 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2011 | 9092 | 0.040 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 204 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 133 | 0.030 |
Why?
|
| Illinois | 1 | 2017 | 531 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 305 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 1978 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 482 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 647 | 0.020 |
Why?
|
| Jaundice, Obstructive | 1 | 2012 | 11 | 0.020 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2012 | 12 | 0.020 |
Why?
|
| Ampulla of Vater | 1 | 2012 | 25 | 0.020 |
Why?
|
| Gallbladder | 1 | 2012 | 33 | 0.020 |
Why?
|
| Electroporation | 1 | 2012 | 57 | 0.020 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2012 | 68 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 2012 | 121 | 0.020 |
Why?
|
| Radiology, Interventional | 1 | 2012 | 67 | 0.020 |
Why?
|
| Ablation Techniques | 1 | 2012 | 41 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 125 | 0.020 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2011 | 17 | 0.020 |
Why?
|
| Photochemotherapy | 1 | 2012 | 101 | 0.020 |
Why?
|
| Drainage | 1 | 2012 | 170 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 203 | 0.020 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2011 | 62 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 393 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2012 | 235 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 415 | 0.020 |
Why?
|
| Embolization, Therapeutic | 1 | 2012 | 279 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 769 | 0.020 |
Why?
|
| Stents | 1 | 2012 | 425 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2011 | 327 | 0.020 |
Why?
|
| Male | 2 | 2011 | 45738 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 473 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 1102 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 1536 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2012 | 591 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 516 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 1567 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 701 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1534 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 3601 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2012 | 1201 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 2787 | 0.010 |
Why?
|
| Mutation | 1 | 2012 | 4373 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 12591 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 28957 | 0.000 |
Why?
|